Clinical trials: Coagulation Protein Disorders
Heavy Menstrual Bleeding, Bleeding Disorder
Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
The goal of this multicenter prospective observational study and registry of U.S. adolescents and young adults with heritable bleeding disorders is to determine the bleeding outcomes, satisfaction, hemostatic parameter changes…
- Conditions
- Heavy Menstrual Bleeding, Bleeding Disorder, Von Willebrand Diseases
- Trial name
- HMB-BD (NCT05916469)
- Testing
- Levonorgestrel Intrauterine System, Norethindrone Acetate
- Where
- 8 sites in United States
- Volunteers
- 300 people
- Sponsor
- Oregon Health and Science University
Hemophilia
A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia A or B
The purpose of this non-interventional, observational, real-world study is to find out what are the real-world experiences of people living with hemophilia A or B[OK1.1] who start the study medicine (called marstacimab) in…
- Trial name
- NCT07859527
- Testing
- Marstacimab
- Volunteers
- 100 people
- Sponsor
- Pfizer
Hemophilia A, Hemophilia B
A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of ALN-AT3SC in healthy volunteers and Hemophilia A or B patients.
- Trial name
- NCT02035605
- Testing
- ALN-AT3SC, Sterile Normal Saline (0.9% NaCl)
- Where
- 14 sites in United States, Bulgaria and 3 more
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Sanofi
Hemophilia
A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient
The purpose of this study is to assess the safety and tolerability, pharmacokinetics and pharmacodynamics of subcutaneous MG1113 in the multiple ascending dose study in patients with severe hemophilia.
- Trial name
- NCT05493631
- Testing
- MG1113
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- GC Biopharma Corp
Hemophilia B, Hemophilia B, Moderately Severe or Severe
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
The BeCoMe-9 Study (BE-101-01) is a Phase 1/2, first in human, multi-center, open-label, dose-escalation study to evaluate the safety and clinical activity of a single intravenous (IV) dose of BE-101 in adults with moderately…
- Trial name
- NCT06611436
- Testing
- BE-101
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Be Biopharma
Hemophilia B
HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients
This is an open-label, single-dose, multi-center, multinational trial to demonstrate the efficacy of AMT-061 and to further describe its safety profile. The study drug is identified as AAV5-hFIXco-Padua (AMT- 061).
- Trial name
- NCT03569891
- Testing
- AAV5-hFIXco-Padua, Factor IX (FIX)
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 67 people
- Sponsor
- CSL Behring
Chronic Myeloproliferative Disorders, Leukemia
Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003082
- Testing
- monoclonal antibody A27.15, monoclonal antibody E2.3
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Arizona
Hemophilia A, Prophylaxis of Bleeding
An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.
This is an observational study in which data from people with hemophilia A who decide on their own or by recommendation of their doctors to take Jivi are collected and studied.
- Trial name
- JOIHA (NCT05643560)
- Testing
- Damoctocog alfa pegol (Jivi, BAY94-9027)
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Bayer
Von Willebrand Diseases
Von Willebrand Factor in Pregnancy (VIP) Study
In pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100%, specific guidance is lacking for delivery planning in…
- Trial name
- VIP (NCT04146376)
- Testing
- Use of a postpartum diary and additional blood draws, VWF replacement therapy with Wilate, Tranexamic acid
- Where
- 11 sites in United States
- Volunteers
- 110 people
- Sponsor
- University of Washington
Hemophilia A
Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients
Title: Comparison of different prophylaxis regimens for hemophilia A pediatric patients Principal Investigator: Assistant Professor Darintr Sosothikul, MD Research Question: Does different factor VIII dosage effect outcome of…
- Trial name
- NCT02727647
- Testing
- FVIII
- Where
- Thailand
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Hemophilia A or B
PF-06741086 Multiple Dose Study in Severe Hemophilia
This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of PF-06741086 in subjects with severe hemophilia.
- Trial name
- NCT02974855
- Testing
- PF-06741086
- Where
- 10 sites in United States, Chile and 4 more
- Volunteers
- 27 people
- Sponsor
- Pfizer
Von Willebrand's Disease (VWD)
To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
Primary Objective: -To characterize the pharmacokinetics (PK) of BIVV001 after a single intravenous (IV) administration, as assessed by factor VIII (FVIII) activity determined by the one-stage activated partial thromboplastin…
- Trial name
- NCT04770935
- Testing
- efanesoctocog alfa (BIVV001)
- Where
- 4 sites in United States, France
- Volunteers
- 6 people
- Sponsor
- Bioverativ, a Sanofi company
Severe Haemophilia
Occupational Integration of Adults With Severe Haemophilia in France: a Study Based on the FranceCoag Cohort
Severe haemophilia and subsequent arthropathy result in joint pain, disability and impaired health-related quality of life. Improvements in haemophilia care over the last decades might lead to expectation of a near-normal quality…
- Trial name
- INTHEMO (NCT03301376)
- Where
- France
- Volunteers
- 590 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Von Willebrand Disease
Willebrand International Non-interventional Global Surveillance
Collect information about WILLFACT or WILFACTIN in their real life clinical use and identify the therapeutic practices in an international environment.
- Trial name
- NCT01949220
- Where
- 18 sites in Belgium, Czechia and 5 more
- Volunteers
- 80 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Hemophilia
Restricting Blood Flow in Improving Muscle Strength in Patients With Hemophilic Arthropathy
Background. The main physical sequela of patients with hemophilia is the development of a progressive, degenerative intra-articular lesion, known as hemophilic arthropathy).
- Trial name
- NCT05039008
- Testing
- Blood flow restriction
- Where
- Spain
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Investigación en Hemofilia y Fisioterapia
Chronic Myeloproliferative Disorders, Kidney Cancer
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00295997
- Testing
- anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
Hemophilia A
Prophylaxis Versus on Demand Treatment for Children With Hemophilia A
Comparison of the effect of three times a week prophylaxis on all bleeds with on-demand treatment for children with severe Hemophilia A.
- Trial name
- NCT01810666
- Testing
- Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Bayer
Attention Deficit Disorder With Hyperactivity, Asthma
Study of an Intervention to Improve Problem List Accuracy and Use
The aim of this study is to identify patients with problem list gaps and intervene to correct these gaps by creating clinical decision support interventions that alert providers to likely problem list gaps and offer clinicians…
- Conditions
- Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer
- Trial name
- MAPLE (NCT01105923)
- Testing
- MAPLE
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Brigham and Women's Hospital
Hemophilia A, Severe, Hemophilia Arthropathy
Effect of Exercise in Pediatric Hemophilia
This study investigates the effect of exercise training on pain, physical activity and quality of life in pediatric hemophilia patients.
- Trial name
- NCT04754997
- Testing
- Traditional exercise training, Specific exercise training
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Hasan Kalyoncu University
Healthy Volunteer
LTA Assessement Using Aggregometer TA-8V (Stago®)
Exploring platelet functions requires aggregation tests platelet. The Haematology Laboratory of Hospices Civils de Lyon currently has two new TA-8V plate aggregation automatons® (Stago).
- Trial name
- NORMAGREG (NCT04269603)
- Testing
- Take blood (TA-8V (Stago®)
- Where
- France
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.